Ulcerative colitis.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
10 09 2020
10 09 2020
Historique:
accepted:
21
07
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
16
6
2021
Statut:
epublish
Résumé
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis. UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries. An improved understanding of the mechanisms underlying UC has led to the emergence of new treatments. Since the early 2000s, anti-tumour necrosis factor (TNF) treatment has significantly improved treatment outcomes. Advances in medical treatments have enabled a paradigm shift in treatment goals from symptomatic relief to endoscopic and histological healing to achieve better long-term outcomes and, consequently, diagnostic modalities have also been improved to monitor disease activity more tightly. Despite these improvements in patient care, a substantial proportion of patients, for example, those who are refractory to medical treatment or those who develop colitis-associated colorectal dysplasia or cancer, still require restorative proctocolectomy. The development of novel drugs and improvement of the treatment strategy by implementing personalized medicine are warranted to achieve optimal disease control. However, delineating the aetiology of UC is necessary to ultimately achieve disease cure.
Identifiants
pubmed: 32913180
doi: 10.1038/s41572-020-0205-x
pii: 10.1038/s41572-020-0205-x
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Références
Wilks, S. Morbid appearances in the intestine of Miss Bankes. Med. Gaz. 2, 264–265 (1859). This paper is the first historical report of UC.
Hibi, T. & Ogata, H. Novel pathophysiological concepts of inflammatory bowel disease. J. Gastroenterol. 41, 10–16 (2006).
pubmed: 16501852
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L. & Colombel, J.-F. Ulcerative colitis. Lancet 389, 1756–1770 (2017).
pubmed: 27914657
pmcid: 27914657
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G. & Long, M. D. ACG clinical guideline: ulcerative colitis in adults. Am. J. Gastroenterol. 114, 384–413 (2019). This paper describes the clinical guidelines on the management of UC recommended by the American College of Gastroenterology.
pubmed: 30840605
Matsuoka, K. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J. Gastroenterol. 53, 305–353 (2018).
pubmed: 29429045
pmcid: 5847182
Magro, F. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J. Crohns Colitis 11, 649–670 (2017). Consensus guidelines on the diagnosis and management of UC by the European Crohn’s and Colitis Organisation.
pubmed: 28158501
Truelove, S. C. & Witts, L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 2, 1041–1048 (1955). This paper describes the results from a clinical trial on the use of steroids in UC.
pubmed: 13260656
Gallo, G., Kotze, P. G. & Spinelli, A. Surgery in ulcerative colitis: When? How? Best Pract. Res. Clin. Gastroenterol. 32–33, 71–78 (2018).
pubmed: 30060941
Ungaro, R., Colombel, J.-F., Lissoos, T. & Peyrin-Biroulet, L. A treat-to-target update in ulcerative colitis: a systematic review. Am. J. Gastroenterol. 114, 874–883 (2019).
pubmed: 30908297
pmcid: 6553548
Colombel, J.-F., D’haens, G., Lee, W.-J., Petersson, J. & Panaccione, R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J. Crohns Colitis 14, 254–266 (2020).
pubmed: 31403666
Peyrin-Biroulet, L. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am. J. Gastroenterol. 110, 1324–1338 (2015). Consensus statements on treat-to-target strategy in the management of UC.
pubmed: 26303131
Ozaki, R. et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J. Crohn’s Colitis 12, 1288–1294 (2018).
Peyrin-Biroulet, L., Bressenot, A. & Kampman, W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin. Gastroenterol. Hepatol. 12, 929–934.e2 (2014).
pubmed: 23911875
Bernstein, C. N. et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 101, 1559–1568 (2006).
Bitton, A. et al. Epidemiology of inflammatory bowel disease in Québec: recent trends. Inflamm. Bowel Dis. 20, 1770–1776 (2014).
pubmed: 25159452
Leddin, D., Tamim, H. & Levy, A. R. Decreasing incidence of inflammatory bowel disease in Eastern Canada: a population database study. BMC Gastroenterol. 14, 140 (2014).
pubmed: 4134124
pmcid: 4134124
Torabi, M. et al. Geographical variation and factors associated with inflammatory bowel disease in a Central Canadian province. Inflamm. Bowel Dis. 26, 581–590 (2020).
pubmed: 31504519
Coward, S. et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156, 1345–1353.e4 (2019).
pubmed: 30639677
Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2017). A systematic review providing an overview of the global epidemiology of IBD.
pubmed: 29050646
Ng, S. C. et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am. J. Gastroenterol. 114, 107–115 (2019).
pubmed: 30177785
Banerjee, R. et al. IBD in India: similar phenotype but different demographics than the west. J. Clin. Gastroenterol. https://doi.org/10.1097/MCG.0000000000001282 (2019).
doi: 10.1097/MCG.0000000000001282
Kedia, S. & Ahuja, V. Epidemiology of inflammatory bowel disease in India: the Great Shift East. Inflamm. Intest. Dis. 2, 102–115 (2017).
pubmed: 30018961
pmcid: 5988149
Perminow, G. et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005–07, showing increased incidence in Crohn’s disease. Scand. J. Gastroenterol. 44, 446–456 (2009).
pubmed: 19117240
Malmborg, P., Grahnquist, L., Lindholm, J., Montgomery, S. & Hildebrand, H. Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm county, 2002–2007. J. Pediatr. Gastroenterol. Nutr. 57, 29–34 (2013).
pubmed: 23459320
Benchimol, E. I. et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am. J. Gastroenterol. 112, 1120 (2017).
pubmed: 28417994
pmcid: 5527278
Muise, A. M., Snapper, S. B. & Kugathasan, S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology 143, 285–288 (2012).
pubmed: 22727850
Shah, S. C. et al. Sex-based differences in incidence of inflammatory bowel diseases—pooled analysis of population-based studies from western countries. Gastroenterology 155, 1079–1089.e3 (2018).
Benchimol, E. I. et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am. J. Gastroenterol. 110, 553–563 (2015).
pubmed: 25756238
Ananthakrishnan, A. N. Environmental triggers for inflammatory bowel disease. Curr. Gastroenterol. Rep. 15, 302 (2013).
pubmed: 23250702
pmcid: 3537164
Bernstein, C. N. et al. World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015. J. Clin. Gastroenterol. 50, 803–818 (2016).
pubmed: 27741097
Wang, P. et al. Smoking and inflammatory bowel disease: a comparison of China, India, and the USA. Dig. Dis. Sci. 63, 2703–2713 (2018).
pubmed: 29862485
pmcid: 6435261
Amarapurkar, A. D. et al. Risk factors for inflammatory bowel disease: a prospective multi-center study. Indian J. Gastroenterol. 37, 189–195 (2018).
pubmed: 29987750
Lerner, A. & Matthias, T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun. Rev. 14, 479–489 (2015).
pubmed: 25676324
Wang, Y.-F. et al. Multicenter case-control study of the risk factors for ulcerative colitis in China. World J. Gastroenterol. 19, 1827–1833 (2013).
pubmed: 23555172
pmcid: 3607760
Benchimol, E. I. et al. Rural and urban residence during early life is associated with risk of inflammatory bowel disease: a population-based inception and birth cohort study. Am. J. Gastroenterol. 112, 1412–1422 (2017).
pubmed: 28741616
pmcid: 5596205
Ungaro, R. et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am. J. Gastroenterol. 109, 1728–1738 (2014).
pubmed: 25223575
Lewis, J. D. & Abreu, M. T. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology 152, 398–414.e6 (2017).
pubmed: 27793606
Marrie, R. A. et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol. Psychiatr. Sci. 28, 333–342 (2019).
pubmed: 29098977
Bonaz, B. L. & Bernstein, C. N. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 144, 36–49 (2013).
pubmed: 23063970
Myrelid, P., Landerholm, K., Nordenvall, C., Pinkney, T. D. & Andersson, R. E. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am. J. Gastroenterol. 112, 1311–1319 (2017).
pubmed: 28653667
Parian, A. et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 66, 1390–1397 (2017).
pubmed: 27196594
Eaden, J. A., Abrams, K. R. & Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526–535 (2001).
pubmed: 11247898
pmcid: 1728259
Olén, O. et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 395, 123–131 (2020).
Bernstein, C. N. et al. The impact of inflammatory bowel disease in Canada 2018: extra-intestinal diseases in IBD. J. Can. Assoc. Gastroenterol. 2, S73–S80 (2019).
pubmed: 31294387
Desai, D. et al. Colorectal cancers in ulcerative colitis from a low-prevalence area for colon cancer. World J. Gastroenterol. 21, 3644–3649 (2015).
pubmed: 25834332
pmcid: 4375589
Wang, Y. N. et al. Clinical characteristics of ulcerative colitis-related colorectal cancer in Chinese patients. J. Dig. Dis. 18, 684–690 (2017).
pubmed: 29119678
Keller, D. S., Windsor, A., Cohen, R. & Chand, M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech. Coloproctol. 23, 3–13 (2019).
pubmed: 30701345
Moody, G. A., Jayanthi, V., Probert, C. S., Mac Kay, H. & Mayberry, J. F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur. J. Gastroenterol. Hepatol. 8, 1179–1183 (1996).
pubmed: 8980937
Eaden, J., Abrams, K., Ekbom, A., Jackson, E. & Mayberry, J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther. 14, 145–153 (2000).
pubmed: 10651654
Bye, W. A., Nguyen, T. M., Parker, C. E., Jairath, V. & East, J. E. Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst. Rev. 9, CD000279 (2017).
pubmed: 28922695
Turpin, W., Goethel, A., Bedrani, L. & Croitoru Mdcm, K. Determinants of IBD Heritability: Genes, Bugs, and More. Inflamm. Bowel Dis. 24, 1133–1148 (2018).
pubmed: 29701818
pmcid: 6093195
Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012). A study of genetics reporting 163 disease susceptibility loci for IBD.
pubmed: 23128233
pmcid: 3491803
Mirkov, M. U., Verstockt, B. & Cleynen, I. Genetics of inflammatory bowel disease: beyond NOD2. Lancet Gastroenterol. Hepatol. 2, 224–234 (2017).
pubmed: 28404137
Spehlmann, M. E. et al. Risk factors in German twins with inflammatory bowel disease: results of a questionnaire-based survey. J. Crohns Colitis 6, 29–42 (2012).
pubmed: 22261525
Halfvarson, J., Bodin, L., Tysk, C., Lindberg, E. & Järnerot, G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124, 1767–1773 (2003).
pubmed: 12806610
Ng, S. C., Woodrow, S., Patel, N., Subhani, J. & Harbord, M. Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm. Bowel Dis. 18, 725–736 (2012).
pubmed: 21557397
van Dongen, J., Slagboom, P. E., Draisma, H. H. M., Martin, N. G. & Boomsma, D. I. The continuing value of twin studies in the omics era. Nat. Rev. Genet. 13, 640–653 (2012).
pubmed: 22847273
Cleynen, I. et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387, 156–167 (2016).
pubmed: 26490195
pmcid: 4714968
Kredel, L. I. et al. T-cell composition in ileal and colonic creeping fat - separating ileal from colonic Crohn’s disease. J. Crohns Colitis 13, 79–91 (2019).
pubmed: 30272118
Yoshitake, S., Kimura, A., Okada, M., Yao, T. & Sasazuki, T. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens 53, 350–358 (1999).
pubmed: 10323339
Inoue, N. et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology 123, 86–91 (2002).
pubmed: 12105836
Martini, E., Krug, S. M., Siegmund, B., Neurath, M. F. & Becker, C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol. Gastroenterol. Hepatol. 4, 33–46 (2017).
pubmed: 28560287
pmcid: 5439240
Van Klinken, B. J., Van der Wal, J. W., Einerhand, A. W., Büller, H. A. & Dekker, J. Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut 44, 387–393 (1999).
pubmed: 10026326
pmcid: 1727426
Gitter, A. H., Wullstein, F., Fromm, M. & Schulzke, J. D. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 121, 1320–1328 (2001).
pubmed: 11729111
Büning, C. et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm. Bowel Dis. 18, 1932–1939 (2012).
pubmed: 22344959
Kaser, A., Adolph, T. E. & Blumberg, R. S. The unfolded protein response and gastrointestinal disease. Semin. Immunopathol. 35, 307–319 (2013).
pubmed: 23588234
pmcid: 3661271
Grootjans, J., Kaser, A., Kaufman, R. J. & Blumberg, R. S. The unfolded protein response in immunity and inflammation. Nat. Rev. Immunol. 16, 469–484 (2016).
pubmed: 27346803
pmcid: 5310224
Krug, S. M. et al. Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis. Mucosal Immunol. 11, 345–356 (2018).
pubmed: 28612843
Neurath, M. F. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 20, 970–979 (2019).
pubmed: 31235952
Jorch, S. K. & Kubes, P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat. Med. 23, 279–287 (2017).
pubmed: 28267716
Bennike, T. B. et al. Neutrophil extracellular traps in ulcerative colitis: a proteome analysis of intestinal biopsies. Inflamm. Bowel Dis. 21, 2052–2067 (2015).
pubmed: 25993694
pmcid: 4603666
Dinallo, V. et al. Neutrophil extracellular traps sustain inflammatory signals in ulcerative colitis. J. Crohns Colitis 13, 772–784 (2019).
pubmed: 30715224
Camoglio, L., Te Velde, A. A., Tigges, A. J., Das, P. K. & Van Deventer, S. J. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. 4, 285–290 (1998).
pubmed: 9836081
Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550–564 (2005).
pubmed: 16083712
Heller, F., Fuss, I. J., Nieuwenhuis, E. E., Blumberg, R. S. & Strober, W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629–638 (2002).
pubmed: 12433369
Danese, S. et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64, 243–249 (2015).
pubmed: 25304132
Kindler, V., Sappino, A. P., Grau, G. E., Piguet, P. F. & Vassalli, P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56, 731–740 (1989).
pubmed: 2647299
Lissner, D. et al. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm. Bowel Dis. 21, 1297–1305 (2015).
pubmed: 25901973
pmcid: 4450953
Hanauer, S. B. et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).
pubmed: 12047962
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005). This study is the first phase III randomized, controlled clinical trial of an anti-TNF agent for UC.
pubmed: 16339095
Uhlig, H. H. et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309–318 (2006).
pubmed: 16919486
Kobayashi, T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut 57, 1682–1689 (2008).
pubmed: 18653729
Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 375, 1946–1960 (2016).
pubmed: 27959607
Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201–1214 (2019).
pubmed: 31553833
Gerlach, K. et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat. Immunol. 15, 676–686 (2014).
pubmed: 24908389
Nishida, A. et al. Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm. Bowel Dis. 22, 303–314 (2016).
pubmed: 26752465
Russell, S. E. et al. IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunol. 9, 1193–1204 (2016).
pubmed: 26813344
Scheibe, K. et al. Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology 156, 1082–1097.e11 (2019).
pubmed: 30452921
Gordon, I. O. et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment. Pharmacol. Ther. 47, 922–939 (2018).
pubmed: 29411405
pmcid: 5842117
Harusato, A. et al. IL-36γ signaling controls the induced regulatory T cell-Th9 cell balance via NFκB activation and STAT transcription factors. Mucosal Immunol. 10, 1455–1467 (2017).
pubmed: 28327619
pmcid: 5610052
Sonnenburg, J. L. & Bäckhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature 535, 56–64 (2016).
pubmed: 27383980
pmcid: 5991619
Machiels, K. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275–1283 (2014).
pubmed: 24021287
Halfvarson, J. et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol. 2, 17004 (2017).
pubmed: 28191884
pmcid: 5319707
Schulthess, J. et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 50, 432–445.e7 (2019).
pubmed: 30683619
pmcid: 6382411
Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102–109.e6 (2015).
pubmed: 25857665
Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218–1228 (2017).
pubmed: 28214091
Rossen, N. G. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110–118.e4 (2015).
pubmed: 25836986
Zheng, L. et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J. Immunol. 199, 2976–2984 (2017).
pubmed: 28893958
pmcid: 5636678
Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015–5022 (2006).
pubmed: 16585598
Fischer, A. et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 65, 1642–1664 (2016).
pubmed: 26209553
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).
pubmed: 23964932
Wei, S.-C. et al. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan society of inflammatory bowel disease. Intest. Res. 15, 266–284 (2017).
pubmed: 28670225
pmcid: 5478753
Fausel, R. A., Kornbluth, A. & Dubinsky, M. C. The first endoscopy in suspected inflammatory bowel disease. Gastrointest. Endosc. Clin. N. Am. 26, 593–610 (2016).
pubmed: 27633590
American Society for Gastrointestinal Endoscopy Standards of Practice Committee. et al. The role of endoscopy in inflammatory bowel disease. Gastrointest. Endosc. 81, 1101–1121.e1-13 (2015).
Chutkan, R. K., Scherl, E. & Waye, J. D. Colonoscopy in inflammatory bowel disease. Gastrointest. Endosc. Clin. N. Am. 12, 463–483 (2002).
pubmed: 12486939
Langner, C. et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch. 464, 511–527 (2014).
pubmed: 24487791
Su, H.-J. et al. Inflammatory bowel disease and its treatment in 2018: global and Taiwanese status updates. J. Formos. Med. Assoc. 118, 1083–1092 (2019).
pubmed: 30054112
D’Haens, G. et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132, 763–786 (2007).
pubmed: 17258735
Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625–1629 (1987).
pubmed: 3317057
Peyrin-Biroulet, L. et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin. Gastroenterol. Hepatol. 14, 348–354.e17 (2016).
pubmed: 26071941
Fagerhol, M. K., Dale, I. & Andersson, T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull. Eur. Physiopathol. Respir. 16, 273–282 (1980).
pubmed: 7225633
Guerrant, R. L. et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J. Clin. Microbiol. 30, 1238–1242 (1992).
pubmed: 1583125
pmcid: 265257
van Rheenen, P. F., Van de Vijver, E. & Fidler, V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 341, c3369 (2010).
pubmed: 20634346
pmcid: 2904879
Walsham, N. E. & Sherwood, R. A. Fecal calprotectin in inflammatory bowel disease. Clin. Exp. Gastroenterol. 9, 21–29 (2016).
pubmed: 26869808
pmcid: 4734737
Lin, W.-C. et al. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J. Gastroenterol. 21, 13566–13573 (2015).
pubmed: 26730169
pmcid: 4690187
Menees, S. B., Powell, C., Kurlander, J., Goel, A. & Chey, W. D. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol. 110, 444–454 (2015).
pubmed: 25732419
Poullis, A., Foster, R., Northfield, T. C. & Mendall, M. A. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 675–681 (2002).
pubmed: 11929384
Sipponen, T. et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment. Pharmacol. Ther. 28, 1221–1229 (2008).
pubmed: 18752630
Holtman, G. A. et al. Evaluation of point-of-care test calprotectin and lactoferrin for inflammatory bowel disease among children with chronic gastrointestinal symptoms. Fam. Pract. 34, 400–406 (2017).
pubmed: 27535331
D’Haens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2218–2224 (2012).
pubmed: 22344983
Reenaers, C. et al. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol. J. 6, 1117–1125 (2018).
pubmed: 30288273
pmcid: 6169045
Ministro, P. & Martins, D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev. Gastroenterol. Hepatol. 11, 317–328 (2017).
pubmed: 28276813
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I. & Bjarnason, I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123, 450–460 (2002).
pubmed: 12145798
Hübenthal, M. et al. Sparse modeling reveals miRNA signatures for diagnostics of inflammatory bowel disease. PLoS ONE 10, e0140155 (2015).
pubmed: 26466382
pmcid: 4605644
Zhang, H., Zeng, Z., Mukherjee, A. & Shen, B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev. Mol. Diagn. 18, 867–886 (2018).
pubmed: 30152711
Allocca, M. et al. Accuracy of Humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: a prospective study. J. Crohns Colitis 12, 1385–1391 (2018).
pubmed: 30085066
pmcid: 6260119
Kinoshita, K. et al. Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study. J. Gastroenterol. 54, 521–529 (2019).
pubmed: 30519747
Sagami, S. et al. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Aliment. Pharmacol. Ther. 51, 1373–1383 (2020).
pubmed: 32383166
Okabayashi, S. et al. A simple 1-day colon capsule endoscopy procedure demonstrated to be a highly acceptable monitoring tool for ulcerative colitis. Inflamm. Bowel Dis. 24, 2404–2412 (2018).
pubmed: 29718414
Shi, H. Y. et al. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest. Endosc. 86, 1139–1146.e6 (2017).
pubmed: 28713062
Li, J. & Leung, W. K. Colon capsule endoscopy for inflammatory bowel disease. J. Dig. Dis. 19, 386–394 (2018).
pubmed: 29869371
Maeda, Y. et al. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest. Endosc. 89, 408–415 (2019).
pubmed: 30268542
Ullman, T. A. & Itzkowitz, S. H. Intestinal inflammation and cancer. Gastroenterology 140, 1807–1816 (2011).
pubmed: 21530747
Watanabe, T. et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 151, 1122–1130 (2016).
pubmed: 27523980
Harbord, M. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J. Crohns Colitis 11, 769–784 (2017).
pubmed: 28513805
Van Assche, G., Vermeire, S. & Rutgeerts, P. Management of acute severe ulcerative colitis. Gut 60, 130–133 (2011). Consensus guidelines on treatment of UC by the European Crohn’s and Colitis Organisation.
pubmed: 21030524
Nguyen, G. C. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian association of gastroenterology. Gastroenterology 146, 835–848.e6 (2014).
pubmed: 24462530
pmcid: 24462530
Travis, S. P. et al. Predicting outcome in severe ulcerative colitis. Gut 38, 905–910 (1996).
pubmed: 8984031
pmcid: 1383200
Higashiyama, M. et al. Management of elderly ulcerative colitis in Japan. J. Gastroenterol. 54, 571–586 (2019).
pubmed: 31025187
pmcid: 6685935
Ruemmele, F. M. & Turner, D. Differences in the management of pediatric and adult onset ulcerative colitis — lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J. Crohns Colitis 8, 1–4 (2014).
pubmed: 24230969
Sturm, A. et al. European Crohn’s and Colitis organisation topical review on IBD in the elderly: table 1. J. Crohns Colitis https://doi.org/10.1093/ecco-jcc/jjw188 (2016).
pubmed: 27797918
pmcid: 4892354
doi: 10.1093/ecco-jcc/jjw188
Marteau, P. et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54, 960–965 (2005).
pubmed: 15951542
pmcid: 1774619
Sandborn, W. J. et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 143, 1218–1226.e2 (2012).
pubmed: 22892337
Herfarth, H. et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology 155, 1098–1108.e9 (2018).
pubmed: 29964043
pmcid: 6174092
Nielsen, O. H., Steenholdt, C., Juhl, C. B. & Rogler, G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: a systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 20, 100271 (2020).
pubmed: 32300735
pmcid: 7152823
Colombel, J. F. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141, 1194–1201 (2011).
pubmed: 21723220
Panaccione, R. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146, 392–400.e3 (2014).
Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257–265.e1–3 (2012).
pubmed: 22062358
Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 85–95 (2014).
pubmed: 23735746
Colombel, J.-F. et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66, 839–851 (2017).
pubmed: 26893500
pmcid: 26893500
Sands, B. E. et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N. Engl. J. Med. 381, 1215–1226 (2019).
pubmed: 31553834
Sandborn, W. J. et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 158, 562–572.e12 (2020).
pubmed: 31470005
Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723–1736 (2017).
pubmed: 28467869
FDA. FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). FDA https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (2019).
Sandborn, W. J. et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment. Pharmacol. Ther. 50, 1068–1076 (2019).
pubmed: 31599001
pmcid: 6899755
Samuel, S. et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm. Bowel Dis. 19, 1858–1866 (2013).
pubmed: 23660997
pmcid: 4526131
Coakley, B. A., Telem, D., Nguyen, S., Dallas, K. & Divino, C. M. Prolonged preoperative hospitalization correlates with worse outcomes after colectomy for acute fulminant ulcerative colitis. Surgery 153, 242–248 (2013).
Targownik, L. E., Singh, H., Nugent, Z. & Bernstein, C. N. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am. J. Gastroenterol. 107, 1228–1235 (2012).
pubmed: 22613902
Kaplan, G. G. et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am. J. Gastroenterol. 107, 1879–1887 (2012).
pubmed: 23165448
Eriksson, C. et al. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963–2010. Aliment. Pharmacol. Ther. 46, 748–757 (2017).
pubmed: 28833287
Schineis, C. et al. Colectomy with ileostomy for severe ulcerative colitis-postoperative complications and risk factors. Int. J. Colorectal Dis. 35, 387–394 (2020).
pubmed: 31865435
Gu, J., Stocchi, L., Remzi, F. & Kiran, R. P. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Colorectal Dis. 15, 1123–1129 (2013).
pubmed: 23627886
Madbouly, K. M. et al. Perioperative blood transfusions increase infectious complications after ileoanal pouch procedures (IPAA). Int. J. Colorectal Dis. 21, 807–813 (2006).
pubmed: 16583193
Zittan, E. et al. Preoperative anti-tumor necrosis factor therapy in patients with ulcerative colitis is not associated with an increased risk of infectious and noninfectious complications after ileal pouch-anal anastomosis. Inflamm. Bowel Dis. 22, 2442–2447 (2016).
pubmed: 27607335
Mor, I. J. et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis. Colon Rectum 51, 1202–1207 (2008).
pubmed: 18536964
Selvasekar, C. R. et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J. Am. Coll. Surg. 204, 956–962 (2007).
pubmed: 17481518
Yung, D. E. et al. Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease. Inflamm. Bowel Dis. 24, 2327–2338 (2018).
pubmed: 29788385
Gu, J., Remzi, F. H., Shen, B., Vogel, J. D. & Kiran, R. P. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy. Dis. Colon Rectum 56, 1243–1252 (2013).
pubmed: 24104999
Remzi, F. H. et al. Restorative proctocolectomy: an example of how surgery evolves in response to paradigm shifts in care. Colorectal Dis. 19, 1003–1012 (2017).
pubmed: 28481467
Ahmed Ali, U. et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst. Rev. 1, CD006267 (2009).
Shen, B., Remzi, F. H., Lavery, I. C., Lashner, B. A. & Fazio, V. W. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin. Gastroenterol. Hepatol. 6, 145–158 (2008).
pubmed: 18237865
Garrett, J. W. & Drossman, D. A. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology 99, 90–96 (1990).
pubmed: 2188874
De Dombal, F. T., Burton, I. & Goligher, J. C. The early and late results of surgical treatment for Crohn’s disease. Br. J. Surg. 58, 805–816 (1971).
pubmed: 5124848
Guyatt, G. et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96, 804–810 (1989).
pubmed: 2644154
Love, J. R., Irvine, E. J. & Fedorak, R. N. Quality of life in inflammatory bowel disease. J. Clin. Gastroenterol. 14, 15–19 (1992).
pubmed: 1556402
Irvine, E. J., Zhou, Q. & Thompson, A. K. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s relapse prevention trial. Am. J. Gastroenterol. 91, 1571–1578 (1996).
pubmed: 8759664
Casellas, F., López-Vivancos, J., Vergara, M. & Malagelada, J. Impact of inflammatory bowel disease on health-related quality of life. Dig. Dis. 17, 208–218 (1999).
pubmed: 10754360
Lönnfors, S. et al. IBD and health-related quality of life – discovering the true impact. J. Crohns Colitis 8, 1281–1286 (2014).
pubmed: 24662394
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual. Life Outcomes 4, 79 (2006).
pmcid: 1629006
WHO. International classification of functioning, disability and health (ICF). WHO http://www.who.int/classifications/icf/en/ (2018).
Cieza, A. & Stucki, G. The international classification of functioning disability and health: its development process and content validity. Eur. J. Phys. Rehabil. Med. 44, 303–313 (2008).
pubmed: 18762740
Peyrin-Biroulet, L. et al. Disability in inflammatory bowel diseases: developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. Inflamm. Bowel Dis. 16, 15–22 (2010).
pubmed: 19610077
Ananthakrishnan, A. N. et al. Permanent work disability in Crohn’s disease. Am. J. Gastroenterol. 103, 154–161 (2008).
pubmed: 18076736
Thompson, P. W. & Pegley, F. S. A comparison of disability measured by the stanford health assessment questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. Br. J. Rheumatol. 30, 298–300 (1991).
pubmed: 1863829
Dasgupta, B. et al. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res. 66, 1799–1807 (2014).
Noseworthy, J. H., Vandervoort, M. K., Wong, C. J. & Ebers, G. C. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 40, 971–975 (1990).
pubmed: 2189084
Butzkueven, H. et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J. Neurol. Neurosurg. Psychiatry 85, 1190–1197 (2014).
pubmed: 24532785
pmcid: 4215289
Peyrin-Biroulet, L. et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 61, 241–247 (2012).
Gower-Rousseau, C. et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut 66, 588–596 (2017).
pubmed: 26646934
Lee, Y. et al. Disability in restorative proctocolectomy recipients measured using the inflammatory bowel disease disability index. J. Crohns Colitis 10, 1378–1384 (2016).
pubmed: 27282401
Lichtenstein, G. R., Cohen, R., Yamashita, B. & Diamond, R. H. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J. Clin. Gastroenterol. 40, 669–677 (2006).
pubmed: 16940876
Peyrin-Biroulet, L., Germain, A., Patel, A. S. & Lindsay, J. O. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment. Pharmacol. Ther. 44, 807–816 (2016).
pubmed: 27534519
Shafer, L. A. et al. Independent validation of a self-report version of the IBD disability index (IBDDI) in a population-based cohort of IBD patients. Inflamm. Bowel Dis. 24, 766–774 (2018).
pubmed: 29554260
Chiricozzi, A. et al. Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. Eur. J. Dermatol. 25, 64–69 (2015).
pubmed: 25514606
Mercuri, S. R., Gregorio, G. & Brianti, P. Quality of life of psoriasis patients measured by the PSOdisk: a new visual method for assessing the impact of the disease. G. Ital. Dermatol. Venereol. 152, 424–431 (2017).
pubmed: 28906085
Ghosh, S. et al. Development of the IBD Disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm. Bowel Dis. 23, 333–340 (2017).
pubmed: 28146002
pmcid: 5319390
Levenstein, S. et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am. J. Gastroenterol. 89, 1219–1225 (1994).
pubmed: 8053438
Nahon, S. et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2086–2091 (2012).
pubmed: 22294486
Mikocka-Walus, A. et al. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 14, 829–835.e1 (2016).
pubmed: 26820402
Bitton, A. et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 98, 2203–2208 (2003).
pubmed: 14572569
Christensen, B. et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin. Gastroenterol. Hepatol. 15, 1557–1564.e1 (2017).
pubmed: 28238954
pmcid: 5618439
Colombel, J.-F. et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779–2789 (2018).
pubmed: 29096949
Adedokun, O. J. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 147, 1296–1307.e5 (2014).
pubmed: 25173754
Kobayashi, T. et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J. Gastroenterol. 51, 241–251 (2016).
pubmed: 26162647
Papamichael, K. et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 14, 543–549 (2016).
pubmed: 26681486
Afif, W. et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105, 1133–1139 (2010).
pubmed: 20145610
pmcid: 6937708
Kobayashi, T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. J. Gastroenterol. 51, 241–251 (2016).
pubmed: 26162647
Vande Casteele, N. et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148, 1320–1329.e3 (2015).
pubmed: 25724455
Roda, G., Jharap, B., Neeraj, N. & Colombel, J.-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol. 7, e135 (2016).
pubmed: 26741065
pmcid: 4737871
Peyrin-Biroulet, L. et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 17, 838–846.e2 (2019).
pubmed: 29935327
Baker, K. F. & Isaacs, J. D. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann. Rheum. Dis. 77, 175–187 (2018).
pubmed: 28765121
Feagan, B. G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389, 1699–1709 (2017).
pubmed: 28411872
Ma, C., Jairath, V., Khanna, R. & Feagan, B. G. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opin. Investig. Drugs 27, 649–660 (2018).
pubmed: 30056776
Vermeire, S. et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384, 309–318 (2014).
pubmed: 24814090
Vermeire, S. et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 390, 135–144 (2017).
pubmed: 28527704
Yoshimura, N. et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology 149, 1775–1783.e2 (2015).
pubmed: 26327130
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W. & Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375–381 (2005).
pubmed: 15947078
Sandborn, W. J. et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374, 1754–1762 (2016).
pubmed: 27144850
Vermeire, S. et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389, 266–275 (2017).
pubmed: 27988142
pmcid: 27988142
D’Amico, F., Fiorino, G., Furfaro, F., Allocca, M. & Danese, S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin. Investig. Drugs 27, 595–599 (2018).
pubmed: 29938545
Hansen, J. J. & Sartor, R. B. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr. Treat. Options Gastroenterol. 13, 105–120 (2015).
pubmed: 25595930
pmcid: 4364996
Barber, G. E. et al. Genetic markers predict primary non-response and durable response to anti-TNF biologic therapies in Crohn’s disease. Am. J. Gastroenterol. 111, 1816–1822 (2016).
pubmed: 27596696
pmcid: 5143156
Boyapati, R. K., Kalla, R., Satsangi, J. & Ho, G.-T. Biomarkers in search of precision medicine in IBD. Am. J. Gastroenterol. 111, 1682–1690 (2016).
pubmed: 27670602
West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017).
pubmed: 28368383
pmcid: 5420447
Choung, R. S. et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment. Pharmacol. Ther. 43, 1300–1310 (2016).
pubmed: 27117843
Doherty, M. K. et al. Fecal microbiota signatures are associated with response to Ustekinumab therapy among Crohn’s disease patients. mBio https://doi.org/10.1128/mBio.02120-17 (2018).
pubmed: 29535202
pmcid: 5850325
doi: 10.1128/mBio.02120-17
Zhou, Y. et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems https://doi.org/10.1128/mSystems.00188-17 (2018).
pubmed: 30637338
pmcid: 6306508
doi: 10.1128/mSystems.00188-17
Arijs, I. et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn’s disease. Inflamm. Bowel Dis. 16, 2090–2098 (2010).
pubmed: 20848504
Gamo, K. et al. Gene signature-based approach identified MEK1/2 as a potential target associated with relapse after anti-TNFα treatment for Crohn’s disease. Inflamm. Bowel Dis. 24, 1251–1265 (2018).
pubmed: 29669006
pmcid: 6176896
Kaplan, G. G. et al. The impact of inflammatory bowel disease in Canada 2018: epidemiology. J. Can. Assoc. Gastroenterol. 2, S6–S16 (2019).
pubmed: 31294381
Danese, S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61, 918–932 (2012).
pubmed: 22115827